Why are CJC-1295 and ipamorelin sold together?

They act on different receptors that both feed into pituitary growth hormone signalling, and the pairing is offered on the theory that engaging both is better than engaging one. That is a mechanistic rationale, not established human evidence.

Can you take BPC-157 and TB-500 together?

The combination is widely marketed. Neither compound has substantial human trial evidence individually, and combining two unapproved substances increases the unknowns rather than resolving them.

Are blends safer because the amounts are smaller?

That reasoning does not hold. Combining substances introduces interaction questions that have not been characterised, and quantity is a matter for a licensed provider in any case.

Do compounding pharmacies prepare these blends?

Some components sit in an FDA category that raises significant safety concerns for compounding. Anyone supplying a blend should be able to account for each component individually.

CJC-1295 and ipamorelin blends

Peptides in this category are rarely marketed alone. CJC-1295 with ipamorelin is the most common pairing; BPC-157 with TB-500 is the second. The pairings are not arbitrary, and understanding the logic makes it easier to evaluate what you are being offered.

It also makes the central problem obvious: combining two compounds that individually lack human evidence does not produce evidence. It multiplies the unknowns.

Common pairingCJC-1295 + ipamorelin
Second pairingBPC-157 + TB-500
US statusNone approved
SportWADA-prohibited

The logic behind the pairings

CJC-1295 is a GHRH analogue; ipamorelin acts at the ghrelin receptor. The rationale offered for combining them is that they approach pituitary signalling from two different directions, and that doing both is more effective than doing either.

BPC-157 with TB-500 follows a different rationale: two compounds discussed in preclinical recovery research, paired on the theory that their mechanisms are complementary.

Both rationales are mechanistically coherent stories. Neither is the same thing as evidence that the combination does anything useful in a person.

What combining does to the evidence picture

For a combination to be assessed properly you would want human data on each component and then on the combination. In this category you generally have neither.

If something goes wrong, you cannot attribute it to one component or the other.
If nothing happens, you cannot tell which component failed or whether either was in the vial.
Interaction effects between two unapproved compounds have not been characterised in people.
Blended preparations make the sourcing question harder, because now the identity and purity of two substances are in question rather than one.

Status of the components

Compound / Class / US approval / Compounding position
Compound	Class	US approval	Compounding position
CJC-1295	GHRH analogue	None	No approved status
Ipamorelin	Ghrelin receptor agonist	None	FDA safety-concern category
BPC-157	Gastric peptide fragment	None	FDA safety-concern category
TB-500	Thymosin beta-4 related	None	No approved status

All four fall under the WADA prohibited list for this class.

What to ask if you are offered a blend

Ask which pharmacy prepares it and under what authority for each component. Ask what testing the finished preparation goes through. Ask what is being measured before and during, and what result would cause the clinician to stop.

Dosing is determined by a licensed provider.

How we verify providers

Questions

Peptide blends: common questions

Why are CJC-1295 and ipamorelin sold together?: They act on different receptors that both feed into pituitary growth hormone signalling, and the pairing is offered on the theory that engaging both is better than engaging one. That is a mechanistic rationale, not established human evidence.
Can you take BPC-157 and TB-500 together?: The combination is widely marketed. Neither compound has substantial human trial evidence individually, and combining two unapproved substances increases the unknowns rather than resolving them.
Are blends safer because the amounts are smaller?: That reasoning does not hold. Combining substances introduces interaction questions that have not been characterised, and quantity is a matter for a licensed provider in any case.
Do compounding pharmacies prepare these blends?: Some components sit in an FDA category that raises significant safety concerns for compounding. Anyone supplying a blend should be able to account for each component individually.

Talk to a licensed provider before considering any of this

Peptides are prescriber territory, and the useful first step is finding out what is actually going on rather than picking a compound. We connect you with licensed providers who investigate first.

Find a licensed provider

TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.

We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.

Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.